We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Some Inclusion Bodies Protect Cells from Damage by Toxic Misfolded Proteins

By LabMedica International staff writers
Posted on 20 Dec 2012
Researchers studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease reported in a recent paper that inclusion bodies, i.e., sites of accumulation of toxic misfolded proteins, which have traditionally been thought to accompany onset of this type of disease, actually have a cell-biological function that is not necessarily related to the disease conditions.

Investigators at the Hebrew University of Jerusalem (Israel) have been studying for several years the JUNQ (juxtanuclear quality control compartment), a novel organellar structure, which serves as a cellular processing center for misfolded and aggregated proteins. More...
JUNQ was shown to be important in managing cellular protein folding quality control, the cellular response to protein aggregation, the formation of prions, and in protecting cells from the toxic effect of aggregation.

In the current paper, which was published in the September 25, 2012, issue of the journal Proceedings of the National Academy of Sciences of the United States of America, the investigators elaborated on the function of JUNQ by presenting direct evidence of a quality control function for JUNQ inclusions in human cultured cells. JUNQ compartments concentrated soluble misfolded proteins together with chaperones and proteasomes, and facilitated their degradation.

The data further showed that the accumulation of insoluble aggregates in the JUNQ inhibited the degradation of other misfolded proteins by sequestering the essential chaperone Hsp70 (heat shock protein 70) and thereby blocking the path of quality control substrates to the proteasome. Rerouting toxic aggregates from the JUNQ to an insoluble polyQ inclusion restored the JUNQ protein degradation function and rescued cell viability.

The authors concluded that toxic and nontoxic inclusions represented different sites of aggregate deposition, with different cell biological properties. They proposed a new approach to treating neurodegenerative diseases that would enhance cellular ability to actively enclose harmful aggregates within protective inclusions, thereby neutralizing the toxic proteins.

Related Links:
Hebrew University of Jerusalem



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.